Jun 09, 2023 (AB Digital via COMTEX) -- The Opium Addiction market growth is driven by factors like increase in the prevalence of Opium Addiction, investments in research and development,…
The Kentucky Opioid Abatement Advisory Commission held its first public hearing Monday, July 17, to discuss funding development of an opioid-use disorder treatment using the psychedelic drug ibogaine with some of the…
Today, Daniel Cameron, Attorney General for the US State of Kentucky, announced that the State will take $42 million from its portion of the Opioid Settlement Funds and use it…
Source: https://www.benzinga.com/markets/cannabis/22/06/27799330/10-psychedelics-ceos-to-pay-attention-to-in-2022-1 2020 and 2021 were defining years for the burgeoning psychedelics industry. In 2021 alone, more than $730 million were invested into various psychedelic companies, both private and public. Businesses around…
People seeking treatment to overcome opioid addiction are often stymied by the treatment itself. Many don’t have access to drugs like methadone or buprenorphine or can’t make it to a…
A joint venture between DemeRx and Atai Life Sciences has been cleared by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to start enrolment for a Phase I/IIa trial…
NEW YORK, March 10, 2021 /PRNewswire/ — DemeRx IB, Inc. (DemeRx), an atai Life Sciences (atai) platform company focused on developing ibogaine for the treatment of opioid use disorder (OUD), today announced the…
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved the launch of a Phase I/IIa trial of DemeRx and atai Life Sciences’ ibogaine HCl (DMX-1002) for the treatment…
BERLIN and MIAMI, Jan. 24, 2020 /PRNewswire/ — ATAI Life Sciences AG (“ATAI” or the “Company”), a global biotech platform that envisions an end to mental illnesses, today announced an investment in two separate joint ventures (JV)…
INTERNATIONAL – The World Economic Forum’s billionaire audience in Davos took a break from the problem of climate change to listen to the story of a company developing a hallucinogenic…
